One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
UCSF prints >50 and <50, omitting exactly 50; the EUA renal instruction is not limited to those headings.
What to reconcile: Confirm the exact product, indication, renal measure and full source before prescribing.
Open this note and its source referencesUse the full EUA eligibility and duration rules. Do not interpret a brief institutional all-indications heading as unrestricted use.
Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
| Renal population | Source-specific dose / instruction |
|---|---|
| Any degree of renal impairment | No renal dose adjustment recommended |
Molnupiravir - renal instruction
| Renal population | Source-specific dose / instruction |
|---|---|
| Any degree of renal impairment | No renal dose adjustment recommended |
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
RDM63-official-molnupiravir-4baa2d799b-C1 · Source locator: EUA limitations; dosage 2.1/2.2; renal impairment 8.6
Adult EUA treatment described: 800 mg orally every 12 hours for 5 days, begun within 5 days of symptoms, when alternatives are not accessible or clinically appropriate.
Not for patients under 18, prophylaxis or starting treatment for patients hospitalized because of COVID-19. Pregnancy, contraception and lactation counseling remain necessary.
The selected fact sheet says PK below eGFR 30 or on dialysis was not evaluated; lack of expected exposure change is not a completed dialysis study.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=molnupiravir&s1=RDM63-official-molnupiravir-4baa2d799b&h1=990432adfbe79b2fc76082e02263504f2c1ea8ea47699d718a382082dffd2309